Margo Georgiadis, Flagship CEO-Partner and CEO of Montai Therapeutics, shares Montai’s journey from R&D company to drug development company and how its platform is marrying untapped chemistry and powerful biological pathways to make leaps in how we treat chronic disease. More from Flagship @ JPM2024 here.
More from:
Human Health
Essay
The Future of Health Starts Before Disease Does
What If We Could See Disease Coming and Stop It?
Amanda Kay on a New Approach to Biopharma Partnerships
Pioneering Partnerships: Advancing a Portfolio of Novel Medicines and Vaccines with GSK
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
